Outcomes and toxicities in patients with diffuse-large B cell lymphoma involving the gastrointestinal tract and digestive organs.

Autor:	Manzar GS; Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, United States., Cha EE; Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, United States., Corrigan KL; Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, United States., Yoder AK; Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, United States., Schrank BR; Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, United States., Nasr LF; Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, United States., Chihara D; Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, United States., Castillo LM; Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, United States., Nair R; Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, United States., Jain P; Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, United States., Neelapu SS; Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, United States., Rodriguez MA; Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, United States., Strati P; Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, United States., Nastoupil LJ; Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, United States., Gunther JR; Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, United States., Dabaja BS; Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, United States., Pinnix CC; Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, United States., Wu SY; Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, United States., Fang PQ; Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, United States.
Jazyk:	angličtina
Zdroj:	Frontiers in oncology [Front Oncol] 2024 Sep 11; Vol. 14, pp. 1447020. Date of Electronic Publication: 2024 Sep 11 (Print Publication: 2024).
DOI:	10.3389/fonc.2024.1447020
Abstrakt:	Background: Diffuse large B-cell lymphoma (DLBCL) involving the gastrointestinal (GI) organs is rare, and real-world outcomes after combined modality therapy (CMT) with systemic therapy (ST) and radiotherapy (RT) are not well-characterized, particularly in the contemporary era. We characterized outcomes in a large cohort of GI-DLBCL patients treated with ST alone or CMT. Methods: Patients with GI-DLBCL treated at a single institution were retrospectively reviewed. Kaplan-Meier and Cox regression models estimated survival. Multivariable analyses were conducted using the Cox proportional hazards model. Results: Of 204 patients, gastric involvement was most common (63%). Most presented with early-stage disease (61%). All patients received ST and 65 patients (32%) received RT, 88% as part of first-line CMT. Median dose was 36 Gy (IQR 30.6-39.6) in 18 fractions (IQR 17-22). Median follow-up was 46 months. Five-year overall survival (OS) and progression-free survival (PFS) was 88% and 84%, respectively; complete response (CR) rate was 82%. Improved OS associated with low IPI ( p =0.001), fewer chemotherapy lines ( p <0.001), early stage ( p <0.006), and CR ( p <0.001). Survival did not differ by RT receipt ( p >0.25). Only early stage and CR correlated with improved OS on multivariable analysis. Stomach-directed RT vs. RT to other sites correlated with improved PFS and OS ( p <0.04). Patients with early stage DLBCL treated with CMT in the post-rituximab era had equivalent OS vs. ST alone, even with fewer chemotherapy cycles ( p <0.02; median of 4 with RT vs. 6 cycles without). Fifty patients had bulky disease (≥7.5 cm), of whom 18 (36%) had early stage disease. Among patients with bulky disease, 5 (10%) developed relapse at the initial site of disease bulk. Four of the 5 patients did not receive consolidative radiation. Among these 4 patients, 3 relapsed only in their initial site of bulky disease. Of 191 patients with luminal GI-DLBCL, n =4 (2.1%) developed perforation; only one received RT. Acute Grade 3 toxicities were reported in 41.2% of patients, and 12 (5.8%) patients had late Grade 3 toxicities, 99% attributed to chemotherapy. Conclusion: GI-DLBCL patients have favorable outcomes after CMT with minimal late toxicity. CMT may be offered with abridged systemic regimens with equivalent outcomes. Stomach directed-RT may mitigate relapse risk associated with incomplete disease response or bulky disease. Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. The author(s) declared that they were an editorial board member of Frontiers, at the time of submission. This had no impact on the peer review process and the final decision. (Copyright © 2024 Manzar, Cha, Corrigan, Yoder, Schrank, Nasr, Chihara, Castillo, Nair, Jain, Neelapu, Rodriguez, Strati, Nastoupil, Gunther, Dabaja, Pinnix, Wu and Fang.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu